BridgeMD
New treatment option for Left Ventricular Thrombus
Official title Anticoagulation in Post MI LV Thrombus Trial in Nepal
ClinicalTrials.gov ID: NCT05794399
What this study is testing
What is Rivaroxaban?
Rivaroxaban is an investigational medicine, given as an once-daily infusion into a vein, being studied as a potential treatment for left ventricular thrombus.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Introduction: The prevalence of left ventricular(LV) thrombus after acute myocardial infarction has decreased with thrombolysis and primary angioplasty intervention worldwide. However, most of the patients in our country present late after the onset of ischemia resulting in a comparable increase proportion of late presentation MI compared to developed countries.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patients aged \>18 years hospitalized with the diagnosis of acute STEMI and
- Presence of LV thrombus which is confirmed with cardiac MRI.
You likely can't join if
- Bleeding risk Active bleeding; history of intracranial hemorrhage; clinically significant gastrointestinal bleeding within 12 months before...
- Undergoing anticoagulation therapy
- Cardiovascular condition Cardiac shock; uncontrolled blood pressure (SBP ≥180 mmHg); planned CABG within 3 months; suspicious Pseudo-ventricular...
- Concomitant diseases Severe chronic or acute renal failure (CrCl \<50 mL/min at screening or pre-randomization); significant liver disease; current...
- Other conditions adjudicated by investigators to be unsuitable for anticoagulation
- Pregnant women and participants with any cognitive impairment.
The study team makes the final eligibility decision.
Where it's taking place
- Kathmandu, Bagmati, Nepal
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Kathmandu, Bagmati, Nepal. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.